ALX Oncology (ALXO) Competitors $0.72 +0.03 (+3.90%) Closing price 04:00 PM EasternExtended Trading$0.74 +0.02 (+2.76%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO vs. OCGN, CYBN, IKT, TLSA, LRMR, MOLN, PBYI, GLSI, NBTX, and NLTXShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Ocugen (OCGN), Cybin (CYBN), Inhibikase Therapeutics (IKT), Tiziana Life Sciences (TLSA), Larimar Therapeutics (LRMR), Molecular Partners (MOLN), Puma Biotechnology (PBYI), Greenwich LifeSciences (GLSI), Nanobiotix (NBTX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Ocugen Cybin Inhibikase Therapeutics Tiziana Life Sciences Larimar Therapeutics Molecular Partners Puma Biotechnology Greenwich LifeSciences Nanobiotix Neoleukin Therapeutics ALX Oncology (NASDAQ:ALXO) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability. Does the MarketBeat Community believe in ALXO or OCGN? Ocugen received 58 more outperform votes than ALX Oncology when rated by MarketBeat users. Likewise, 71.07% of users gave Ocugen an outperform vote while only 64.71% of users gave ALX Oncology an outperform vote. CompanyUnderperformOutperformALX OncologyOutperform Votes5564.71% Underperform Votes3035.29% OcugenOutperform Votes11371.07% Underperform Votes4628.93% Do analysts recommend ALXO or OCGN? ALX Oncology currently has a consensus target price of $4.14, indicating a potential upside of 477.24%. Ocugen has a consensus target price of $6.33, indicating a potential upside of 786.15%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of ALXO or OCGN? 98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 33.4% of ALX Oncology shares are owned by company insiders. Comparatively, 4.3% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer ALXO or OCGN? In the previous week, ALX Oncology had 3 more articles in the media than Ocugen. MarketBeat recorded 5 mentions for ALX Oncology and 2 mentions for Ocugen. ALX Oncology's average media sentiment score of 0.80 beat Ocugen's score of 0.62 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, ALXO or OCGN? Ocugen has higher revenue and earnings than ALX Oncology. Ocugen is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$160.80M-$2.60-0.28Ocugen$4.06M51.47-$63.08M-$0.19-3.76 Which has more risk & volatility, ALXO or OCGN? ALX Oncology has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.88, meaning that its share price is 288% more volatile than the S&P 500. Is ALXO or OCGN more profitable? ALX Oncology has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. ALX Oncology's return on equity of -93.02% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -93.02% -70.67% Ocugen -532.51%-154.75%-90.79% SummaryALX Oncology beats Ocugen on 9 of the 17 factors compared between the two stocks. Remove Ads Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.29M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-0.247.2324.5519.25Price / SalesN/A230.77395.7294.10Price / CashN/A65.6738.1634.64Price / Book0.196.617.064.46Net Income-$160.80M$142.13M$3.19B$247.07M7 Day Performance-3.33%2.79%1.49%3.05%1 Month Performance-31.70%2.70%5.87%-2.85%1 Year Performance-93.88%-4.42%14.94%4.63% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology4.216 of 5 stars$0.72+3.9%$4.14+477.2%-94.1%$38.29MN/A-0.2440OCGNOcugen0.9313 of 5 stars$0.57+6.6%$6.33+1,006.1%-61.1%$167.21M$4.06M-3.1880Gap UpCYBNCybin2.7879 of 5 stars$7.65+1.1%$86.00+1,024.2%N/A$164.30MN/A-1.7550IKTInhibikase Therapeutics0.9792 of 5 stars$2.36+4.9%$6.50+175.4%+6.3%$163.69M$260,000.00-0.886TLSATiziana Life Sciences0.5505 of 5 stars$1.55-1.3%N/A+132.3%$163.36MN/A0.008Gap DownLRMRLarimar Therapeutics2.3636 of 5 stars$2.55-1.5%$20.13+689.2%-71.8%$162.71MN/A-2.2230Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageMOLNMolecular Partners1.5542 of 5 stars$4.03-7.0%$12.00+198.1%-2.5%$162.46M$4.97M-1.87180PBYIPuma Biotechnology4.0281 of 5 stars$3.24-2.4%$7.00+116.0%-34.9%$160.74M$230.47M6.75200Positive NewsGLSIGreenwich LifeSciences1.6316 of 5 stars$12.21+1.8%$38.00+211.2%-42.7%$160.50MN/A-15.263NBTXNanobiotix1.8749 of 5 stars$3.33+2.5%$12.00+260.4%-41.9%$156.95M$36.22M0.00100NLTXNeoleukin TherapeuticsN/A$16.70-0.6%N/A-71.5%$156.95MN/A-5.3790High Trading Volume Remove Ads Related Companies and Tools Related Companies Ocugen Competitors Cybin Competitors Inhibikase Therapeutics Competitors Tiziana Life Sciences Competitors Larimar Therapeutics Competitors Molecular Partners Competitors Puma Biotechnology Competitors Greenwich LifeSciences Competitors Nanobiotix Competitors Neoleukin Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALXO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALXO Stock Free ALXO Stock Alerts